Skip to main
AYTU
AYTU logo

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma’s current valuation presents an attractive investment opportunity, as indicated by recent adjustments in price targets based on net present value analysis, suggesting significant upside potential. The company's lead product, EXXUA, has shown promising results in clinical trials for improving depression symptoms with a favorable side effect profile, thereby enhancing its market potential. Additionally, the anticipated launch of EXXUA for major depressive disorder in Q4 2025 is expected to serve as a strong catalyst for stock performance, further reinforcing the positive outlook on the firm's financial trajectory.

Bears say

Aytu BioPharma faces fundamental challenges reflected in its reliance on third-party sales for a diverse portfolio of prescription therapeutics and consumer health products, which may limit its operational control and profitability. Despite having a pipeline that includes prospective treatments for niche conditions, the financial outlook is clouded by significant investor concerns regarding the unmet needs in the market, particularly related to the side effects of existing therapies, impacting its potential market share. Additionally, while the stock appears undervalued based on estimates of future sales, the persistent uncertainties surrounding its growth prospects could hinder investor confidence and adoption in the long term.

Aytu BioScience (AYTU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.